ADIL

Adial Pharmaceuticals has announced the acquisition of Azora Therapeutics, alongside a financing package of up to $64 million to support the combined entity. The deal represents a significant strategic expansion for Adial beyond its existing pipeline. No additional terms of the acquisition or financing structure were disclosed in the headline.

Adial Pharmaceuticals announced the acquisition of Azora Therapeutics alongside a concurrent private placement financing of up to $64 million. The combined company intends to advance a pipeline focused on ulcerative colitis, with a Phase 1 trial initiation targeted for mid-2027. No financial terms of the acquisition itself were disclosed in the announcement.